Scarica l'app Stockscreener
1.69
0.60%
0.01
Precedente Chiudi:
$1.68
Aprire:
$1.69
Volume 24 ore:
22,052
Relative Volume:
0.06
Capitalizzazione di mercato:
$4.72M
Reddito:
Utile/perdita netta:
$-14.11M
Rapporto P/E:
-0.1577
EPS:
-10.7181
Flusso di cassa netto:
$-13.60M
1 W Prestazione:
+11.18%
1M Prestazione:
-8.65%
6M Prestazione:
-46.86%
1 anno Prestazione:
-81.23%
Intervallo 1D:
$1.61
$1.75
Intervallo di 1 settimana:
$1.50
$1.98
Portata 52W:
$1.041
$10.84
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Nome
Processa Pharmaceuticals Inc
Settore
Industria
Telefono
443-776-3133
Indirizzo
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
1.69 | 4.72M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-25 | Iniziato | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Borsa (PCSA) Ultime notizie
Form PRE 14A Processa Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com Canada
Processa Pharmaceuticals files prospectus for 306.574M share sale - scanx.trade
Processa Pharmaceuticals Proposes Reverse Stock Split Following Merger with Vidya Therapeutics - Kalkine Media
Selling stockholders would receive resale proceeds, with none going to Processa (Nasdaq: PCSA). - Stock Titan
Processa Pharmaceuticals Files Amended 8-K/A Including Financials for Vidya Therapeutics Acquisition - Kalkine Media
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com Canada
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com UK
Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push - Investing.com Canada
Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push - Investing.com UK
Processa Pharmaceuticals Inc. (PCSA) Peer Comparison – Compare with Others - Value Research
Processa Pharmaceuticals Inc. (PCSA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Processa Pharmaceuticals Inc. (PCSA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
A doctor on Processa Pharmaceuticals' board will present at two investor conferences on Sept. 10 and 11. - Stock Titan
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Processa Pharmaceuticals Inc. (PCSA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Processa (PCSA) Range: Closes 0.47% Lower at $2.14 in Latest Trading; Next Test: Support at $2.03 and Resistance at $2.25 Frame the RangeDark Pool Volume - vinanet.vn
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control - Stock Titan
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsChaikin Flow - dars.gov.et
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsLinear Regression - vinanet.vn
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsDay Trade Opportunities - dars.gov.et
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com Nigeria
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com UK
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into FocusPercent Above MA - vinanet.vn
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com UK
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals (PCSA) Surges 11.74% to $2.57 — Poised for a Test of $2.70 ResistanceQuality Factor - vinanet.vn
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals Inc (PCSA) Earnings, Actual EPS, EPS Estimates & Results - stocktwits.com
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Form 4 Processa Pharmaceuticals Inc For: 30 July By Investing.com - Investing.com Nigeria
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
Processa Pharmaceuticals Inc Azioni (PCSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Processa Pharmaceuticals Inc Azioni (PCSA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| SKIBSTED RUSSELL | Chief Financial Officer |
May 29 '26 |
Buy |
2.57 |
2,292 |
5,890 |
10,758 |
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):